Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease

Li, Qiang; Huang, Chenlu; Xu, Wei; Hu, Qiankun; Chen, Liang

doi:10.1097/md.0000000000020616

Cited by 10 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ratio of the interquartile range (IQR) of liver stiffness to the median (IQR/M) was calculated and we took the better quality criteria (10 valid measurements, IQR/M < 30%) of FibroScan to analysis. 26,27 FIB-4 was calculated using the following formula: (age [years] × aspartate aminotransferase [AST; U/L])/(platelet [10 9 /L] × (alanine aminotransferase [ALT; U/L]) 1/2 ). 14 The AST, ALT and bilirubin were checked from serum just before operation.…”

Section: What's Newmentioning

confidence: 99%

Clinical and novel application of FibroScan, FIB‐4 and aspartate aminotransferase‐to‐platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction

et al. 2021

View full text Add to dashboard Cite

Background Non‐invasive techniques for liver fibrosis diagnosis are very important for clinician especially in high‐risk patients for liver biopsy. We further explored the diagnostic accuracy of FibroScan, FIB‐4 and aminotransferase‐to‐platelet ratio index (APRI) in identifying liver fibrosis and assess their predictive role for oesophageal varices in patients with hepatocellular carcinoma (HCC). Methods In total, 380 patients who underwent surgery for HCC were included based on retrospective study design. Liver fibrosis was pathologically diagnosed using the Ishak scoring system. Liver stiffness parameters were measured using FibroScan. APRI and FIB‐4 were calculated. Among those, 121 patients who received oesophagogastroduodenoscopic examination underwent variceal evaluation. Results For liver cirrhosis diagnosis with FibroScan, the optimal cut‐off values for the patients with HCC overall, left HCC and right HCC were 8.85, 11.75 and 8.70 kPa (the accuracy were 78.7%, 78.4% and 79.2%, respectively). They had high areas under the receiver operating characteristic curve of 0.84, 0.84 and 0.85. The combined FibroScan, APRI and FIB‐4 had very high specificity (more than 92%) for cirrhosis diagnosis. The optimal cut‐off liver stiffness values for the diagnosis of varices were all 11.2 kPa. For predicting varices, the optimal cut‐off values of FIB‐4 and APRI were 2.64 and 0.71, their accuracy were 64.3%‐78.4%, 69.4% and 72.7%, respectively. Conclusions FibroScan, FIB‐4 and APRI have moderate accuracy for liver fibrosis diagnosis and oesophageal varices prediction in patients with hepatoma. This is a study of these non‐invasive techniques applied in specific hepatoma patients and with inevitable limitations and need future more studies for validation.

show abstract

Section: What's Newmentioning

confidence: 99%

Clinical and novel application of FibroScan, FIB‐4 and aspartate aminotransferase‐to‐platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Transient elastography(TE), which is widely used, can accurately evaluate the inflammation and fibrosis of liver tissue. 8 , 10 Relevant research results suggest that Fibroscan may improve the sensitivity of the diagnosis of liver fibrosis in patients with CHB and ALT levels <2 times the upper normal limit, and that this sensitivity may increase with the progression of liver fibrosis. 17 However, the LSM is affected by inflammation, congestion, cholestasis, different probes, and other factors.…”

Section: Discussionmentioning

confidence: 99%

“…For example, the aspartate aminotransferase‐ (AST‐) to‐platelet ratio index (APRI) and fibrosis‐4 (FIB‐4) are scores showing satisfactory performance to exclude liver cirrhosis. 9 , 10 , 11 Recently, the gamma‐glutamyl transpeptidase‐ (GGT‐) to‐platelet ratio (GPR) has been shown to have the same diagnostic value as APRI and FIB‐4 in assessment of liver fibrosis with CHB, and even it is considered that GPR is more accurate than APRI and FIB‐4 in evaluating liver fibrosis in patients with CHB. 12 , 13 However, there are few data to explore the diagnostic value of GPR for liver fibrosis in patients with concomitant CHB and NAFLD.…”

Section: Introductionmentioning

confidence: 99%

Gamma‐Glutamyl Transpeptidase‐to‐Platelet ratio predicts liver fibrosis in patients with concomitant chronic hepatitis B and nonalcoholic fatty liver disease

Luo

Liang

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Objectives The aim of this study was to compare the correlation of gamma‐glutamyl transpeptidase‐to‐platelet ratio (GPR), aspartate aminotransferase‐to‐platelet ratio index (APRI), fibrosis index‐4 (FIB‐4), and liver stiffness measurement (LSM) in the diagnosis of liver fibrosis, and perform a diagnostic value of GPR for predicting fibrosis in CHB patients with NAFLD. Methods A retrospective study was conducted on CHB patients concurrent with NAFLD between September 2019 and December 2020. They were divided into control group (LSM ≤ 9.7 kpa) and fibrosis group (LSM ≥ 9.8 kpa). Demographic data were collected; ALT, AST, and PLT were also detected. LSM was measured by transient elastography (TE). The GPR, APRI, and FIB‐4 were calculated. The correlation between GPR, APRI, FIB‐4, and LSM was compared. The accuracy of predicting liver fibrosis using GPR, APRI, and FIB‐4 was assessed. Results Eighty‐five CHB patients with NAFLD were enrolled. Multivariate analysis showed that age (p = 0.005), GGT (p = 0.001), and PLT (p = 0.013) were the independent risk factors for LSM. The GPR (p = 0.008), APRI (p = 0.001), and FIB‐4 (p = 0.001) values in fibrosis group were higher than control group. Pearson linear correlation was used to analyze the correlations between LSM and GPR, APRI, and FIB‐4. LSM was correlated with GPR, APRI, and FIB‐4. The AUCs of GPR, APRI, and FIB4 were 0.805, 0.766, and 0.826 in assessing liver fibrosis, respectively. No significant differences in the areas of GPR were comparable to that of APRI and FIB‐4. Conclusion GPR has a good correlation with LSM in assessing liver fibrosis and can be used as a noninvasive index for the assessment of liver fibrosis in patients with concomitant CHB and NAFLD.

show abstract

“…Chronic hepatitis B is the most common chronic liver disease in China. For chronic hepatitis B patients with steatosis, the risks of cirrhosis and hepatocellular carcinoma are increased (15,16). It is important to screen for steatosis in patients with chronic hepatitis B.…”

Section: Original Articlementioning

confidence: 99%

Analysis of liver steatosis analysis and controlled attenuation parameter for grading liver steatosis in patients with chronic hepatitis B

Ren¹,

Xia²,

Zhang³

et al. 2021

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background: Chronic hepatitis B is the most common chronic liver disease in China. For patients with chronic hepatitis B, steatosis increases the risk of cirrhosis and hepatocellular carcinoma. This study aimed to analyze and compare the clinical value of a newly developed ultrasound attenuation parameter, liver steatosis analysis (LiSA), acquired by Hepatus (Mindray, China), and controlled attenuation parameter (CAP), a widely used ultrasound attenuation parameter acquired by FibroScan (Echosens, France), for grading liver steatosis in patients with chronic hepatitis B infection.Methods: A total of 203 patients were divided into two groups according to liver fat content validated by liver biopsy: group 1 (liver fat content <10%) and group 2 (liver fat content ≥10%). All patients underwent LiSA and CAP examinations. Receiver operating characteristic (ROC) curves were calculated for the two ultrasound attenuation tools.Results: Both LiSA and CAP successfully discriminated between patients in group 1 and group 2. ROC curves showed that both tools had good diagnostic ability (AUC: >0.7) for steatosis ≥10%, and the performance of LiSA was significantly better than CAP (AUC: 0.859 vs. 0.801, P=0.048). Using optimal cut-off points, LiSA had specificity and sensitivity of 96.23% and 76.08%, respectively, for the diagnosis of steatosis ≥10%, compared to 91.53% and 72.10%, respectively, for CAP.Conclusions: LiSA and CAP are extremely efficient tools for assessing liver steatosis, even at a low grade. Both parameters are non-invasive, inexpensive, and easy to use, and can provide immediate results with high sensitivity.

show abstract

Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease

Cited by 10 publications

References 38 publications

Clinical and novel application of FibroScan, FIB‐4 and aspartate aminotransferase‐to‐platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction

Clinical and novel application of FibroScan, FIB‐4 and aspartate aminotransferase‐to‐platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction

Gamma‐Glutamyl Transpeptidase‐to‐Platelet ratio predicts liver fibrosis in patients with concomitant chronic hepatitis B and nonalcoholic fatty liver disease

Analysis of liver steatosis analysis and controlled attenuation parameter for grading liver steatosis in patients with chronic hepatitis B

Contact Info

Product

Resources

About